Suppr超能文献

无高危HLA-DR4-DQ8或HLA-DR3-DQ2单倍型的自身抗体阳性个体的特征。

Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes.

作者信息

Redondo Maria J, Cuthbertson David, Steck Andrea K, Herold Kevan C, Oram Richard, Atkinson Mark, Brusko Todd M, Parikh Hemang M, Krischer Jeffrey P, Onengut-Gumuscu Suna, Rich Stephen S, Sosenko Jay M

机构信息

Texas Children's Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.

Health Informatics Institute, University of South Florida, Tampa, FL, USA.

出版信息

Diabetologia. 2025 Mar;68(3):588-601. doi: 10.1007/s00125-024-06338-7. Epub 2024 Dec 13.

Abstract

AIMS/HYPOTHESIS: Many studies of type 1 diabetes pathogenesis focus on individuals with high-risk HLA haplotypes. We tested the hypothesis that, among islet autoantibody-positive individuals, lacking HLA-DRB104-DQA103-DQB10302 (HLA-DR4-DQ8) and/or HLA-DRB10301-DQA10501-DQB10201 (HLA-DR3-DQ2) is associated with phenotypic differences, compared with those who have these high-risk HLA haplotypes.

METHODS

We classified autoantibody-positive relatives of individuals with type 1 diabetes into four groups based on having both HLA-DR4-DQ8 and HLA-DR3-DQ2 (DR3/DR4; n=1263), HLA-DR4-DQ8 but not HLA-DR3-DQ2 (DR4/non-DR3; n=2340), HLA-DR3-DQ2 but not HLA-DR4-DQ8 (DR3/non-DR4; n=1607) and neither HLA-DR3-DQ2 nor HLA-DR4-DQ8 (DRX/DRX; n=1294). Group comparisons included demographics, metabolic markers and the prevalence of autoantibodies against GAD65 (GADA%), IA-2 (IA-2A%) or insulin (IAA%) at enrolment. A p value <0.01 was considered statistically significant.

RESULTS

IA-2A% was lower in the DRX/DRX group (20.9%) than in the DR4/non-DR3 (38.5%, p<0.001) and DR3/DR4 (44.8%, p<0.001) groups, but similar to the DR3/non-DR4 group (20.0%). Conversely, IAA% was similar in the DRX/DRX (43.4%), DR4/non-DR3 (41.1%) and DR3/DR4 (41.0%) groups, but lower in the DR3/non-DR4 group (30.1%, p<0.001). Participants in the DRX/DRX group were older, with a lower prevalence of White participants and a higher prevalence of overweight/obesity, and higher preserved C-peptide (as measured by a lower Index60) than those in the DR3/DR4 group (all comparisons, p<0.005), a lower prevalence of White or non-Hispanic participants and a lower Index60 than those in the DR4/non-DR3 group, and younger age, a higher prevalence of Hispanic participants and a lower Index60 than those in the DR3/non-DR4 group (all comparisons, p<0.005). Among the 1292 participants who progressed to clinical type 1 diabetes, those in the DR3/non-DR4 group had higher GADA%, lower IA-2A% and lower IAA% than the other groups (all comparisons, p<0.01), and those in the DR3/DR4 group had the youngest age at diagnosis (all comparisons, p<0.001).

CONCLUSIONS/INTERPRETATION: Autoantibody-positive individuals who lack both high-risk HLA haplotypes (DRX/DRX) or have HLA-DR3-DQ2 but lack HLA-DR4-DQ8 (DR3/non-DR4) have phenotypic differences compared with DR3/DR4 and DR4/non-DR3 individuals, suggesting that there is aetiological heterogeneity in type 1 diabetes.

摘要

目的/假设:许多关于1型糖尿病发病机制的研究聚焦于具有高风险HLA单倍型的个体。我们检验了这样一个假设,即在胰岛自身抗体阳性个体中,与具有这些高风险HLA单倍型的个体相比,缺乏HLA - DRB104 - DQA103 - DQB10302(HLA - DR4 - DQ8)和/或HLA - DRB10301 - DQA10501 - DQB10201(HLA - DR3 - DQ2)与表型差异相关。

方法

我们将1型糖尿病患者的自身抗体阳性亲属根据是否同时具有HLA - DR4 - DQ8和HLA - DR3 - DQ2(DR3/DR4;n = 1263)、具有HLA - DR4 - DQ8但不具有HLA - DR3 - DQ2(DR4/非DR3;n = 2340)、具有HLA - DR3 - DQ2但不具有HLA - DR4 - DQ8(DR3/非DR4;n = 1607)以及既不具有HLA - DR3 - DQ2也不具有HLA - DR4 - DQ8(DRX/DRX;n = 1294)分为四组。组间比较包括人口统计学特征、代谢指标以及入组时针对GAD65的自身抗体(GADA%)、IA - 2(IA - 2A%)或胰岛素(IAA%)的患病率。p值<0.01被认为具有统计学意义。

结果

DRX/DRX组的IA - 2A%(20.9%)低于DR4/非DR3组(38.5%,p<0.001)和DR3/DR4组(44.8%,p<0.001),但与DR3/非DR4组(20.0%)相似。相反,DRX/DRX组(43.4%)、DR4/非DR3组(41.1%)和DR3/DR4组(41.0%)的IAA%相似,但DR3/非DR4组的IAA%较低(30.1%,p<0.001)。与DR3/DR4组相比,DRX/DRX组的参与者年龄更大,白人参与者患病率更低,超重/肥胖患病率更高,且保留的C肽水平更高(通过较低的Index60衡量)(所有比较,p<0.005);与DR4/非DR3组相比,白人或非西班牙裔参与者患病率更低,Index60更低;与DR3/非DR4组相比,年龄更小,西班牙裔参与者患病率更高,Index60更低(所有比较,p<0.005)。在进展为临床1型糖尿病的1292名参与者中,DR3/非DR4组的GADA%更高,IA - 2A%和IAA%更低,与其他组相比(所有比较,p<0.01),且DR3/DR4组诊断时年龄最小(所有比较,p<0.001)。

结论/解读:与DR3/DR4和DR4/非DR3个体相比,缺乏两种高风险HLA单倍型(DRX/DRX)或具有HLA - DR3 - DQ2但缺乏HLA - DR4 - DQ8(DR3/非DR4)的自身抗体阳性个体具有表型差异,提示1型糖尿病存在病因异质性。

相似文献

1
Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes.
Diabetologia. 2025 Mar;68(3):588-601. doi: 10.1007/s00125-024-06338-7. Epub 2024 Dec 13.
2
HLA associations in type 1 diabetes among patients not carrying high-risk DR3-DQ2 or DR4-DQ8 haplotypes.
Tissue Antigens. 1999 Dec;54(6):543-51. doi: 10.1034/j.1399-0039.1999.540602.x.
4
Genetic risk markers related to diabetes-associated autoantibodies in young patients with type 1 diabetes in berlin, Germany.
Exp Clin Endocrinol Diabetes. 2010 Apr;118(4):245-9. doi: 10.1055/s-0029-1246213. Epub 2010 Feb 5.
7
HLA-DR-DQ haplotypes and specificity of the initial autoantibody in islet specific autoimmunity.
Pediatr Diabetes. 2020 Nov;21(7):1218-1226. doi: 10.1111/pedi.13073. Epub 2020 Jul 23.
10
Early onset of diabetes in the proband is the major determinant of risk in HLA DR3-DQ2/DR4-DQ8 siblings.
Diabetes. 2014 Mar;63(3):1041-7. doi: 10.2337/db13-0994. Epub 2013 Nov 7.

本文引用的文献

1
Genetic Associations With C-peptide Levels Before Type 1 Diabetes Diagnosis in At-risk Relatives.
J Clin Endocrinol Metab. 2025 Mar 17;110(4):e1046-e1050. doi: 10.1210/clinem/dgae349.
2
A multi-ancestry genome-wide association study in type 1 diabetes.
Hum Mol Genet. 2024 May 18;33(11):958-968. doi: 10.1093/hmg/ddae024.
3
Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes.
N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18.
4
Heterogeneity and endotypes in type 1 diabetes mellitus.
Nat Rev Endocrinol. 2023 Sep;19(9):542-554. doi: 10.1038/s41574-023-00853-0. Epub 2023 Jun 19.
5
Screening and Prevention of Type 1 Diabetes: Where Are We?
J Clin Endocrinol Metab. 2023 Nov 17;108(12):3067-3079. doi: 10.1210/clinem/dgad328.
7
Increased HLA class II risk is associated with a more aggressive presentation of clinical type 1 diabetes.
Acta Paediatr. 2023 Mar;112(3):522-528. doi: 10.1111/apa.16621. Epub 2022 Dec 25.
9
On the road to universal screening for risk of type 1 diabetes.
Lancet Diabetes Endocrinol. 2022 Aug;10(8):554-555. doi: 10.1016/S2213-8587(22)00166-8. Epub 2022 Jul 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验